文献速递肝病

GLP-1受体激动剂与肝硬化合并糖尿病患者肝脏失代偿事件

Glucagon-Like Peptide-1 Receptor Agonists and Hepatic Decompensation Events in Patients With Cirrhosis and Diabetes.
PubMed 文献 · Clin Gastroenterol Hepatol · 2021-07-10

这项基于人群的回顾性队列研究在肝硬化合并2型糖尿病患者中比较GLP-1受体激动剂与DPP-4抑制剂、磺脲类或SGLT-2抑制剂的失代偿事件风险。结果显示,与DPP-4抑制剂或磺脲类相比,GLP-1受体激动剂组任何失代偿发生率显著更低,而与SGLT-2抑制剂直接比较无显著差异。

要点

  • 肝硬化合并糖尿病患者中,GLP-1受体激动剂较DPP-4抑制剂或磺脲类显著降低失代偿风险。
  • GLP-1受体激动剂与SGLT-2抑制剂直接比较,失代偿发生率无显著差异。
  • 腹水、自发性细菌性腹膜炎、肝肾综合征、食管静脉曲张出血等单项事件也呈类似关联。

核心结论

  • 在肝硬化合并2型糖尿病患者中,GLP-1受体激动剂起始者的任何失代偿发生率显著低于DPP-4抑制剂或磺脲类起始者。
  • GLP-1受体激动剂与SGLT-2抑制剂直接比较时,失代偿发生率相似。

研究设计与样本

  • 基于人群的回顾性队列研究,使用IBM MarketScan商业医疗数据库。
  • 构建3个1:1倾向评分匹配的成对队列,分别比较GLP-1受体激动剂与DPP-4抑制剂(2006-2020)、磺脲类(2005-2020)或SGLT-2抑制剂(2013-2020)。
  • 采用as-treated方式随访失代偿事件,控制>90项基线特征。

主要发现

  • 中位随访132天(IQR 73-290天),GLP-1受体激动剂 vs DPP-4抑制剂:任何失代偿105.2 vs 144.0/1000 PY,HR 0.68(95%CI 0.53-0.88;n=1431对)。
  • GLP-1受体激动剂 vs 磺脲类:任何失代偿97.3 vs 144.0/1000 PY,HR 0.64(95%CI 0.48-0.84;n=1246对)。
  • 腹水、自发性细菌性腹膜炎或肝肾综合征:HR 0.66(95%CI 0.45-0.97)和HR 0.66(95%CI 0.46-0.94)。
  • 食管静脉曲张出血:HR 0.62(95%CI 0.41-0.92)和HR 0.59(95%CI 0.37-0.92)。
  • 肝性脑病:HR 0.76(95%CI 0.55-1.06)和HR 0.60(95%CI 0.39-0.92);GLP-1受体激动剂 vs SGLT-2抑制剂任何失代偿103.5 vs 112.8/1000 PY,HR 0.89(95%CI 0.62-1.28)。

临床怎么用

  • 对于肝硬化合并2型糖尿病患者,GLP-1受体激动剂可能较DPP-4抑制剂或磺脲类降低失代偿风险,可作为降糖选择时考虑。
  • GLP-1受体激动剂与SGLT-2抑制剂之间的失代偿风险无显著差异,选择时需综合其他因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The study sought to compare the effectiveness of glucagon-like peptide-1 receptor agonists (GLP-1RAs) with dipeptidyl peptidase-4 (DPP-4) inhibitors, sulfonylureas, or sodium-glucose cotransporter-2 (SGLT-2) inhibitors in reducing decompensation events, among patients with cirrhosis and type 2 diabetes. METHODS: This population-based, retrospective cohort study included patients with type 2 diabetes and cirrhosis, in a commercial healthcare database (IBM MarketScan). We constructed 3 pairwise, 1:1 propensity score (PS)-matched cohorts of adults initiating GLP-1RAs or a comparator medication (ie, DPP-4 inhibitors [2006-2020], sulfonylurea [2005-2020], or SGLT-2 inhibitors [2013-2020]). Patients were followed in an as-treated approach for decompensation events (ie, ascites, spontaneous bacterial peritonitis, hepatorenal syndrome, hepatic encephalopathy, or esophageal variceal hemorrhage). Within each PS-matched cohort, we estimated hazard ratios (HRs) and 95% confidence intervals (CIs), controlling for >90 baseline characteristics. RESULTS: Over 132 days of median follow-up (interquartile range, 73-290 days), PS-matched rates of any decompensation were significantly lower among GLP-1RA initiators, versus DPP-4 inhibitor initiators (105.2 vs 144.0 per 1000 person-years [PY]; HR, 0.68; 95% CI, 0.53-0.88; n = 1431 pairs), and versus sulfonylureas (97.3 vs 144.0 per 1000 PY; HR, 0.64; 95% CI, 0.48-0.84; n = 1246 pairs). Similar, inverse associations were found for individual decompensation events, including ascites, spontaneous bacterial peritonitis, or hepatorenal syndrome (HR, 0.66; 95% CI, 0.45-0.97; and HR, 0.66; 95% CI, 0.46-0.94, respectively); esophageal variceal hemorrhage (HR, 0.62 [95% CI, 0.41-0.92; and HR, 0.59; 95% CI, 0.37-0.92, respectively); and hepatic encephalopathy (HR, 0.76; 95% CI, 0.55-1.06; and HR, 0.60; 95% CI, 0.39-0.92, respectively). Results persisted in subgroups of patients with and without previously decompensated cirrhosis. In contrast, decompensation rates were similar when GLP-1RAs and SGLT-2 inhibitors were directly compared (103.5 vs 112.8 per 1000 PY; HR, 0.89; 95% CI, 0.62-1.28). CONCLUSIONS: Among cirrhotic patients with type 2 diabetes, we find high rates of decompensation, consistent with previous reports; these rates were substantially lower among GLP-1RA initiators compared with DPP-4 inhibitors or sulfonylureas.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Simon TG, Patorno E, Schneeweiss S, et al. Glucagon-Like Peptide-1 Receptor Agonists and Hepatic Decompensation Events in Patients With Cirrhosis and Diabetes. Clin Gastroenterol Hepatol. 2021. PMID: 34256144. doi:10.1016/j.cgh.2021.07.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。